237 related articles for article (PubMed ID: 30097236)
41. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
42. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Hahn AW; Gill DM; Pal SK; Agarwal N
Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
[TBL] [Abstract][Full Text] [Related]
43. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
44. Biomarkers for immunotherapy in urological cancers.
Gust KM; Resch I; D'Andrea D
Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
46. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
47. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
48. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Carlino MS; Long GV
Clin Cancer Res; 2016 Aug; 22(16):3992-8. PubMed ID: 27340279
[TBL] [Abstract][Full Text] [Related]
49. Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials.
Abdel-Rahman O
Crit Rev Oncol Hematol; 2016 Jan; 97():65-71. PubMed ID: 26321371
[TBL] [Abstract][Full Text] [Related]
50. [Myocarditis: Uncommon but severe toxicity of immune checkpoint inhibitors].
Courand PY; Bouali A; Harbaoui B; Cautela J; Thuny F; Lantelme P
Bull Cancer; 2019 Nov; 106(11):1050-1056. PubMed ID: 31627906
[TBL] [Abstract][Full Text] [Related]
51. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
52. Masterful Antibodies: Checkpoint Blockade.
Lonberg N; Korman AJ
Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
[TBL] [Abstract][Full Text] [Related]
53. [Not Available].
Pagès C; Baroudjian B; Lebbé C
Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
[TBL] [Abstract][Full Text] [Related]
54. Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top".
Simonelli M; Persico P; Perrino M; Zucali PA; Navarria P; Pessina F; Scorsetti M; Bello L; Santoro A
Cancer Treat Rev; 2018 Sep; 69():121-131. PubMed ID: 29966936
[TBL] [Abstract][Full Text] [Related]
55. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
[TBL] [Abstract][Full Text] [Related]
56. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
57. Nivolumab in recurrent/metastatic head and neck cancers.
Karabajakian A; Reverdy T; Gau M; Fayette J
Future Oncol; 2018 Mar; 14(7):603-609. PubMed ID: 29130342
[TBL] [Abstract][Full Text] [Related]
58. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
[TBL] [Abstract][Full Text] [Related]
60. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
King GT; Sharma P; Davis SL; Jimeno A
Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
